PubMed Health⌕ Search

Biomedical subjects

M D Ware

Publications and source records attributed to M D Ware.

6 recordsLinked to original sources
PubMed1984

Coagulation and fibrinolysis in estrogen-treated surgically menopausal women.

The short-term effects of different types and doses of estrogen therapy on coagulation and fibrinolysis were studied in 35 surgically menopausal women. Dynamic tests of the coagulation cascade, tests indicative of ongoing, intravascular coagulation, and assessments of coagulation inhibition and fibrinolysis were performed. No clinically abnormal responses were found with the tested regimens--1 and 2 mg of 17 beta-estradiol and 0.625 and 1.25 mg of conjugated equine estrogens. Increased plasminogen antigen and activity were found with the conjugated estrogens but not with the 17 beta-estradiol preparations. The age of the woman had no effect on either the direction or magnitude of response to treatment. Estrogen therapy at the reported doses does not appear to adversely affect the coagulation-fibrinolysis systems of surgically menopausal women. Based on their ability to enhance plasminogen activity, conjugated estrogens may be preferred over the 17 beta-estradiol preparations for this clinical population.

Adult↗
PubMed1983

Lipids and lipoproteins in women after oophorectomy and the response to oestrogen therapy.

The short-term effects of different types and doses of oestrogen on serum lipids and lipoproteins were studied in 35 oophorectomized women. After 3 months treatment, serum cholesterol levels were unaffected by 1 and 2 mg of micronized 17 beta-oestradiol or 0.625 and 1.25 mg of conjugated equine oestrogens. Triglyceride levels were significantly elevated after treatment with 1.25 mg of conjugated oestrogens. A trend towards a higher relative proportion of high-density lipoproteins and a lower relative proportion of low-density lipoproteins was observed for all four oestrogen regimens, however, statistical significance was not achieved. The proportion of very-low-density lipoprotein was unaffected by oestrogen treatment. The age of the oophorectomized women was found to have no effect on either the direction or magnitude of the lipid or lipoprotein responses to oestrogen. Using FSH depression as an index, 1.25 mg of conjugated oestrogens was found to be the most potent of the four oestrogen regimens tested. Therefore, with respect to lipid balance, little additional clinical benefit is achieved by using a more potent regimen and the risk of adverse side effects may be increased.

Adult↗
PubMed1982

Oestrogen--progestin therapy and the lipid balance of post-menopausal women.

The lipid and lipoprotein profiles of 20 post-menopausal women treated with cyclic conjugated oestrogens (0.625 or 1.25 mg) and medroxyprogesterone acetate (10 mg for 7 days) were compared to those of 18 untreated women of similar age and menopausal status. No statistically significant between-group differences were observed during the 18-mth period for cholesterol, triglycerides or lipoprotein distribution. After 12 mth, a significant shift in lipoprotein distribution manifested in the treated and untreated groups. The proportion of high-density lipoproteins significantly increased and that of the low-density lipoproteins significantly decreased. Although the shift was more pronounced in the treated group, there was no significant difference between the treated and untreated groups. These results indicated that such relatively nonandrogenic progestins as medroxyprogesterone acetate, have no adverse effects on the lipid milieu of post-menopausal women when used with long-term oestrogen therapy.

Cholesterol↗
PubMed1981

Benzodiazepines decrease grooming in response to novelty but not ACTH or beta-endorphin.

Excessive grooming in response to intracerebroventricular (ICV) ACTH1-24 was assayed following various doses of diazepam, chlordiazepoxide and flurazepam. Grooming scores were only affected by doses of the benzodiazepines higher than those that depressed locomotor activity. Similarly, diazepam did not affect excessive grooming induced by ICV beta-endorphin, nor did chronic chlordiazepoxide affect ACTH-induced grooming. By contrast similar doses of the benzodiazepines decreased the increased grooming score observed when mice were observed in a novel as opposed to the home cage. This result is consistent with the hypothesis that novel cage-induced grooming is caused by an increase in the ventricular content of ACTH or beta-endorphin, and that the benzodiazepines decrease or prevent this increase. It is not consistent with hypotheses of a functional antagonism between ACTH and benzodiazepines, at least insofar as the mechanisms involved in the production of grooming are concerned.

Adrenocorticotropic Hormone↗